GCOS 2021 - Virtual
Details
If you are interested in registering to attend GCOS 2021 - Virtual, or becoming an IC-OS member click here
CE Information
Target Audience
This conference has been designed for oncologists and cardiologists who are physicians, nurses, pharmacists and basic scientists.
Learning Objectives
After attending this activity, the learner should be able to:
- Identify the optimal cardiovascular disease screening methods before, during and after the cancer therapy
- Describe therapeutic options for effective long term cardiovascular disease management in cancer patients and survivors
- Examine how to develop consensus on best practices for cardiovascular care delivery in cancer patients
- Discuss recommendations for enhancement of cardio-oncology curricula and continuing education.
-
Identify strategies to impact collaborations between oncology and cardiology.
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation of Credit
Physicians: Penn Medicine designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: This activity is approved for 10.25 contact hours.
Pharmacists: This knowledge-based activity is approved for 10.25 ACPE contact hours of continuing pharmacy education credit. JA0000324-0000-21-035-L01-P.
Organised by
Date
- America/New_York
Anne Blaes
Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the...
Read MoreDr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.
Show LessJoseph Carver
Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the...
Read MoreJoseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.
Show LessMike Fradley
Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology...
Read MoreDr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.
Show LessSusan Dent
Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed...
Read MoreDr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.
Show LessSession 1 - Looking Towards The Future: Lessons Learned for Cardio-Oncology from the COVID 19 Pandemic
In this session you will learn more about:
• Challenges encountered in providing adequate care to patients with cardiovascular disease and cancer during COVID
• Innovative strategies to overcome these obstacles in health care deliver for the entire interprofessional tream
• Methods and reocmmendations to implement change in the field of cardio-oncology
Session Chairs:
Iskra Pusik and Marielle Scherrer-Crosbie
Speakers:
Joerg Herrmann and Larry Shulman
Iskra Pusic
Dr. Iskra Pusic is Associate Professor in the Division of Oncology, Department of Internal...
Read MoreDr. Iskra Pusic is Associate Professor in the Division of Oncology, Department of Internal Medicine, at Washington University School of Medicine in St. Louis, MO. Dr. Pusic’s research focuses on long-term complications after allogeneic hematopoietic cell transplantation, particularly Graft-versus-Host Disease (GvHD) and survivorship. Dr. Pusic is a member of the Chronic GvHD Consortium, Clinical Trials Network and Center for International Blood and Marrow Transplant Research - GvHD and Late Effects Working Committees. She was actively involved in the Steering Committee for 2014 and 2021 NIH Chronic GvHD Consensus Development Projects on etiology and prevention of chronic GvHD, and measuring therapeutic response in chronic GvHD trials. She has been a principal investigator on multiple institutional studies and co-investigator on several large multicenter studies focusing on both acute and chronic GvHD. Dr. Pusic was a co-author on a recent Nature publication suggesting that SARS-CoV-2 infection induces a robust antigen-specific, long-lived humoral immune response in humans.
Show LessJoerg Herrmann
Dr. Joerg Herrmann graduated from Ruhr University medical school in Bochum, Germany and completed...
Read MoreDr. Joerg Herrmann graduated from Ruhr University medical school in Bochum, Germany and completed his internal medicine residency and cardiovascular diseases and interventional cardiology fellowship at the Mayo Clinic in Rochester, MN. Thereafter, he joined the division of cardiovascular diseases at the Mayo Clinic Rochester. He is a Professor of Medicine at the Mayo Clinic College of Medicine and currently serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program. His research interests focus on all aspects of cardio-oncology and the pathophysiology, diagnosis, and treatment of atherosclerosis. He has published over 100 articles in peer-reviewed journals and has received NIH grant funding. He also serves as the associated editor of Trends in Cardiovascular Medicine and Practice Update.
Show LessLarry Shulman
Lawrence N. Shulman, MD, MACP, FASCO, is professor of Medicine in the Perelman School of Medicine...
Read MoreLawrence N. Shulman, MD, MACP, FASCO, is professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania, deputy director for Clinical Services at the Abramson Cancer Center. In this capacity, he helps to lead the Cancer Quality program and strategic development of Cancer Services across the University of Pennsylvania Health System. He is the immediate past-chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer’s Quality Integration Committee. He is the director of the Center for Global Cancer Medicine at the Abramson Cancer Center, University of Pennsylvania. He serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda and Haiti, programs for which he plays a seminal leadership role. He sits on the Vice Chancellor’s Advisory Council for Rwanda’s University for Global Health Equity. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership. He is a former member of ASCO’s International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization’s review and revision of their Essential Medicines for Cancer from 2014-2017. He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.
Show LessMarielle Scherrer-Crosbie
Dr Scherrer-Crosbie is the Director of the Echocardiography Laboratory and a Professor of...
Read MoreDr Scherrer-Crosbie is the Director of the Echocardiography Laboratory and a Professor of Medicine at the Hospital of the University of Pennsylvania in Philadelphia, PA, USA. She has a longstanding interest in the interactions of cancer, chemotherapy and heart failure. Throughout her research career, she has also successfully developed a number of novel techniques in the field of echocardiography. She has published over 145 papers and has been continuously funded by the American Heart Association, the American Society of Echocardiography and the NIH. She is involved in the ACC, AHA, APS and ASE, having chaired the cardiovascular sessions at Experimental Biology 2016-2019 and the American Society of Echocardiography 2019 Scientific Sessions. Over the last several years, she has been the PI of 2 multicenter prospective studies, one investigating the value of echocardiographic and blood biomarkers in the prediction of cardiotoxicity in women treated with anthracyclines and trastuzumab, and one investigating the role of statins in the prevention of cardiotoxicity.
Show LessIn this session, you will learn more about:
• The international perspective of cardio-oncology from global IC-OS leaders in Asia, Australia, Europe, North American and South America
• Standard practices and unique regional challenges in the development of cardio-oncology programs
• Strategies to develop new global IC-OS chapters
Session Chairs
Ludhmilla Hajjar, Zaza Iakobishvili, Alicia Okines
Speakers:
Daniel Cehic (Australia), Andres Daniele (Argentina), Geeta Gulati (Nordic Countries), Felipe Garza (Mexico), Sergey Kozhukhov (Ukraine), and Xia Yunlong (China).
Alicia Okines
Dr Alicia Okines is a Consultant Medical Oncologist specializing in breast cancer and acute...
Read MoreDr Alicia Okines is a Consultant Medical Oncologist specializing in breast cancer and acute oncology at the Royal Marsden Hospital in London, and Honorary Faculty at the Institute of Cancer Research in London. Dr Okines studied Pharmacology and then Medicine at the University of Sheffield. During her specialist medical oncology training at the Royal Marsden Hospital, she completed an MD(Res) investigating VEGF and EGFR targeting at the Institute of Cancer Research. Her research interests principally lie in clinical trials and translational research in metastatic breast cancer including brain disease. She is currently leading multi-centre studies in lobular breast cancer and androgen-receptor positive triple negative breast cancer. She has widely published in peer-reviewed journals.
Show LessAndres Daniele
Dr. Andrés j. Daniele is a Head of Cardio-Oncology Department al Instituto de Oncología "Ángel H....
Read MoreDr. Andrés j. Daniele is a Head of Cardio-Oncology Department al Instituto de Oncología "Ángel H. Roffo", Buenos Aires University. He earned his MD degree at La Plata University and completed his residency in cardiology at Favaloro Foundation.. He developed cardio-oncology in Argentina for ten years and actually he is president of Asociación de Cardio-Oncología de la República Argentina and the International CardiOncology - Chapter Argentina.
Show LessFelipe Garza
Dr. Garza is the head of cardio-oncology in Oncare Treatment center, the largest private oncology...
Read MoreDr. Garza is the head of cardio-oncology in Oncare Treatment center, the largest private oncology clinic in the north of the Mexico. His completed his training in internal medicine and cardiology in Monterrey Mexico, followed by a cardio-Oncology fellowship at the Royal Brompton Hospital in London. He is also president of the Mexican chapter of IC-OS. His research interests include cardiac imaging and surveillance in patients with positive HER-2 breast cancer .
Show LessGeeta Gulati
Geeta Gulati, M.D, PhD is a consultant cardiologist in cardio-oncology at Oslo University...
Read MoreGeeta Gulati, M.D, PhD is a consultant cardiologist in cardio-oncology at Oslo University Hospital, Ullevaal, Norway and a senior researcher at Akershus University Hospital, Lorenskog & University of Oslo, Norway. She has established two cardio-oncology units in Norway. Her primary research focus is Randomized Controlled Trials in cardioprotection during cancer treatment. Dr Gulati is the Secretary of the Norwegian Cardiology Society, founder and chair of the Nordic Cardio-Oncology Society and a nucleus member of European Society of Cardiology, Cardio-Oncology Council.
Show LessLudhmila Hajjar
Permanent faculty, associate professor at Universidade de São Paulo Medical School....
Read MorePermanent faculty, associate professor at Universidade de São Paulo Medical School. Cardio-Oncology Coordinator at Instituto do Coração, Hospital das Clínicas, FMUSP. Cardiology Coordinator of the Cancer Institute of the State of São Paulo (ICESP). Coordinator of the Intensive Care Unit at Hospital Paulistano. Coordinator of Cardio-Oncology of the Americas Serviços Médicos Network and director of Science, Innovation and Technology of the Brazilian Society of Cardiology. Participates in the Medical Residency Program and is an advisor of this Graduate Program. Assistance, teaching and research activities.
Show LessSergey Kozhukhov
Head of Department of Clinical Pharmacology and Cardio-Oncology, Head of Cardio-Oncology Center...
Read MoreHead of Department of Clinical Pharmacology and Cardio-Oncology, Head of Cardio-Oncology Center of National Scientific Center «Institute of Cardiology named by M.D.Strazhesko», Kyiv, Ukraine. He has developed cardio-oncology direction in Ukraine and is a Leader of the Cardio-oncology Working Group of Ukrainian Association of Cardiology and the International Cardio-Oncology Society - Chapter Ukraine. His research focuses on designing and implementing strategies to help prevent cardiotoxicity in cancer patients.
Show LessXia Yunlong
President of Dalian Medical University Cardiovascular Hospital. Vice Chairman of Youth Committee...
Read MorePresident of Dalian Medical University Cardiovascular Hospital. Vice Chairman of Youth Committee of Chinese Association of Cardiac Pacing and Electrophysiology Vice Chairman of Youth Committee of Heart Failure Branch of Chinese Medical Doctor Association Vice Chairman of Liaoning Medical Association Cardiology Branch Standing Committee Member, Liaoning Medical Association Electrophysiology and Pace Branch Vice Chairman of the Electrophysiology and Pacing Branch of Dalian Medical Association Vice chairman of Dalian Medical Association Scientific Research Management Branch Director of Liaoning Medical Doctor Association Youth member of Chinese Association of Cardiology Member of the Organizing Committee of Liaoning Medical Doctor Association Member of Arrhythmia Committee of Cardiovascular Disease Branch of Chinese Medical Doctor Association Specialities: The research on the mechanism of atrial arrhythmias (including atrial fibrillation) and catheter ablation treatment, the research on the mechanism of heart failure and electrocardiographic dyssynchron, ventricular hypertrophy and ventricular fibrosis, and the basic and clinical early warning research on the occurrence of ventricular malignant arrhythmias in heart failure
Show LessZaza Iakobishvil
Zaza Iakobishvili, MD, PhD is a director of Community Cardiology Department in Tel Aviv district...
Read MoreZaza Iakobishvili, MD, PhD is a director of Community Cardiology Department in Tel Aviv district of Clalit Health Services since 2018. Dr. Iakobishvili received his MD/PhD in 1988 from the Tbilisi State Medical University and Tbilisi Institute of Human Physiology. He is board certified in internal medicine (1998) and cardiology (2001) in Israel. He worked as attending physician in the cardiac intensive care unit in Rabin Medical Center, Beilinson hospital in 2002-2017. In 2015-2019 he served elected chairman of the Acute Cardiac Care working group and led Acute Coronary Syndrome Israeli Registry (ACSIS). He takes active participation in the ESC ACCA working group on quality of acute cardiac care. In 2018 he was appointed a board member of cardio-oncology study group in Heart Failure Association of ESC. He has established first dedicated cardio-oncology clinic in the Rabin Medical Center in 2013 and chairs the committee of Israel Ministry of Health on cardio-oncology.He organized in 2015 and 2017 the first International cardio-oncology meetings in Israel. Dr. Iakobishvili is actively engaged in the organization of community heart failure and cardio-oncology clinics in Israel. Recently he was appointed to serve as an international advisor for the Journal of American College of Cardiology – Cardio-oncology editorial board. He already serves on the editorial board of Cardio-Oncology, affiliated with the International Cardio-Oncology Society.
Show LessIn this session you will learn more about
• Key developments in basic and translational cardio-oncology
• Important advancements in clinical cardio-oncology from both an oncology and cardiology perspective
• Future directions in clinical, translational and basic cardio-oncology research
Chairs:
Alicia Morgans and Joseph Wu
Speakers:
Evandro de Azambuja, Darryl Leong, and Giselle Melendez
Alicia Morgans
Alicia Morgans, MD, MPH is a Genitourinary Medical Oncologist at the Dana Farber Cancer Institute...
Read MoreAlicia Morgans, MD, MPH is a Genitourinary Medical Oncologist at the Dana Farber Cancer Institute and Faculty in Medicine at Harvard Medical School in Boston. She completed medical school at the University of Pennsylvania School of Medicine, and completed residency at the Hospital of the University of Pennsylvania. She then completed fellowship in hematology/oncology at the Dana Farber Cancer Institute/Massachusetts General combined program before working as faculty at Vanderbilt University, where she earned a Masters of Public Health, and at Northwestern University. She is now serving as the Medical Director of the Survivorship Program at the Dana Farber Cancer Institute, where she specializes in investigating complications of systemic therapy for prostate cancer survivors, including the study of cardiovascular, diabetic, skeletal, and cognitive complications of prostate cancer survivorship. As a current member of the cardio-oncology committee of American Heart Association, she has contributed to the recent AHA Scientific Statement in Circulation: Genomic and Precision Medicine, entitled Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications, and she continues to be an active member of this group. She also acts has a leadership role in several ECOG and NRG trials, all of which include investigations of the complications of hormonal therapy in men with prostate cancer.
Show LessDarryl Leong
Dr. Leong is Associate Professor, Department of Medicine, McMaster University. His clinical...
Read MoreDr. Leong is Associate Professor, Department of Medicine, McMaster University. His clinical interests include cardio-oncology, frailty, multi-morbidity and echocardiography. He is Director of the McMaster University and Hamilton Health Sciences Cardio-Oncology Program. Dr. Leong completed his cardiology training, Doctor of Philosophy, Master of Public Health, and Master of Biostatistics degrees at the University of Adelaide, Australia. He has completed a post-doctorate fellowship in cardiovascular imaging at the Leiden University Medical Centre, the Netherlands, before re-locating to Canada. He is currently a Clinician Scientist of the Heart and Stroke Foundation of Canada. His research is supported by the Canadian Institutes of Health Research and the Canadian Cancer Society, and he has published over 150 manuscripts including all the leading internal medical and cardiovascular journals. His h-index is 47 with approximately 11,000 citations.
Show LessEvandro de Azambuja
Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team)...
Read MoreEvandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium. Dr. de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B) in December 2015. His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer (some of them practice changing in breast cancer) such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib), APHINITY (trastuzumab with or without pertuzumab), Alexandra (adjuvant atezolizumab in triple negative breast cancer) and – in the neoadjuvant setting - the LORELEI trial which tested the efficacy of PI3K inhibition in combination with endocrine therapy. He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society for Medical Oncology (ESMO) and the European Society of Cardiology (ESC). He was past chair of the survivorship of the Belgian Society of Medical Oncology (BSMO). Dr. de Azambuja was a member of the ESMO Executive Board (2018), and currently is an ESMO Council Member (since 2019) and the Chair of the ESMO Fellowship Committee (mandate started in January 2018). He was a member of the ESMO Young Oncologists Committee (YOC) and the ESMO Press & Media Affairs Committee. He is also a faculty member of the ESMO Leaders Generation Program launched in 2016-2017 and Co-Chair of this Programme since 2018. He was appointed as the Chair of the ESMO Leadership Generation Task Force in January 2019. He was appointed as a Breast Faculty Member of ESMO in 2017 and was a Board Member of the Belgian Society of Medical Oncology (BSMO) 2015-2019. Dr. de Azambuja is also a member of the American Society of Clinical Oncology (ASCO) and the Belgian Society of Medical Oncology (BSMO). He is actively involved in editorial boards of the Journal of Clinical Oncology (JCO), “ESMO Open – Cancer Horizons”, and ESMO Perspectives. He has (co)-authored about 240 peer-reviewed articles and 15 book chapters. He has been a member of Education and Scientific Committees of the ESMO, ESMO Breast, EBCC and ECCO meetings.
Show LessGiselle Melendez
Dr. Giselle C. Meléndez is an MD-scientist at Wake Forest School of Medicine in Winston Salem,...
Read MoreDr. Giselle C. Meléndez is an MD-scientist at Wake Forest School of Medicine in Winston Salem, NC. Through basic science, translational, and clinical studies, Dr. Meléndez is deeply committed to improving the understanding of the underlying mechanisms of cardiac complications of cancer therapies and identifying novel interventions to prevent and treat cardiotoxicity in cancer survivors. Specifically, her research focuses on the contribution of extracellular matrix remodeling, inflammation, and cardiac fibrosis to the development of left ventricular dysfunction. She serves as an investigator in clinical trials employing cardiovascular magnetic resonance (CMR) imaging to evaluate subclinical cardiac tissue characteristics; she has adapted these clinical CMR techniques to her pre-clinical rodent and non-human primate models cardiotoxicity to enhance the translatability of her research. Additionally, Dr. Meléndez serves as a peer reviewer of numerous prestigious journals, she is a standing member of the National Institute of Health (NIH), Therapeutic Development and Preclinical Studies study section and she is currently funded by grants from the NIH.
Show LessJoseph Wu
Joseph C. Wu, MD, PhD is Director of Stanford Cardiovascular Institute and Simon H. Stertzer, MD,...
Read MoreJoseph C. Wu, MD, PhD is Director of Stanford Cardiovascular Institute and Simon H. Stertzer, MD, Professor of Medicine and Radiology at Stanford University. Dr. Wu received his MD from Yale University and PhD (Molecular & Medical Pharmacology) at UCLA. He is board certified in cardiology. His lab works on cardiovascular genomics and induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision medicine for patients. Dr. Wu has published >400 manuscripts with H-index of 106 on Google scholar. He is listed as top 1% of highly cited researchers by Web of Science (2018, 2019, 2020). Dr. Wu has received NIH Director’s New Innovator Award, NIH Roadmap Transformative Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama at the White House, American Heart Association (AHA) Distinguished Scientist Award, and Burroughs Wellcome Foundation Innovation in Regulatory Science Award. He serves on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee. Dr. Wu is an elected member of Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association for the Advancement of Science (AAAS), American Association of Physicians (AAP), and National Academy of Medicine (NAM).
Show LessRichard Stephens
Richard Stephens has survived (so far) two cancers, a heart emergency, and continued...
Read MoreRichard Stephens has survived (so far) two cancers, a heart emergency, and continued co-morbidities and late effects. He has participated in four interventional studies and over a dozen others and has donated tissues and samples for research. Richard is in his third decade as a Patient Advocate, which is now his full-time activity. He currently chairs BBMRI-ERIC’s Stakeholder Forum (Europe’s biobanking infrastructure) and NCRI CTRad's Consumer Panel (radiotherapy research). He led the NCRI Consumer Forum 2012-2019 and sit on strategic and/or research groups for NIHR, NHS England, PHE, Genomics England, National Data Collaborative, Macmillan and Cancer Research UK, and works with industry and with patient groups in Europe, Canada and the USA. Richard was the patient co-author of the 2015 Cancer Strategy for England, and in 2020 was an advisor to the UK government on several Covid issues. He was the patient lead for the NCRI-JLA Living With And Beyond Cancer research priority-setting project, with a particular interest in late effects, in view of his own heart problems. Richard helped found the AllTrials campaign and the useMYdata movement, and he is the founding co-Editor-in-Chief of the Journal of Research Involvement and Engagement. He has spoken at meetings of the UK and European Parliaments on the need for international standardisation and co-operation in health research and delivery of care.
Show LessSession 4 - How to talk about your work in a way that maximizes audience engagement.
At this session, you will also hear from a panel of medical experts who will share their experiences of speaking to engage their colleagues.
Learn more about:
• The common mistakes we can easily make when seeking to engage other people in our work
• Easy to apply techniques that you use to give even better presentations
• Tips from other medical experts on what they have learnt about engaging colleagues in their work
Chairs:
Teresa Lopez-Fernandez and Alison Loren
Keynote Speaker:
Craig Millar
Panelists:
Juan Lopez-Mattei, Maryam Lustberg, Randall Oyer, Vijay Rao
Alison Loren
Dr. Loren is currently Professor of Medicine and Vice Chair for Faculty Development in the...
Read MoreDr. Loren is currently Professor of Medicine and Vice Chair for Faculty Development in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Clinically, she is a specialist in allogeneic hematopoietic cell transplantation and her research focuses on fertility preservation and long-term survivorship in these patients. Dr. Loren has a longstanding interest in mentoring and career development, having served as Fellowship Program Director in Hematology/Oncology at Penn prior to taking on her vice chair role. She has given Grand Rounds and spoken nationally on mentorship in general, as well as on difficult situations within the mentoring relationship, and serves as an advisor, mentor, and sponsor to many trainees and junior faculty.
Show LessCraig Millar
Craig helps experts to speak in a way that engages audiences from other disciplines. Based in...
Read MoreCraig helps experts to speak in a way that engages audiences from other disciplines. Based in England, he works with CEO’s, TEDx Speakers and medical experts who have a key presentation coming up. In 2018, he won a Cicero speechwriting award for a talk that was given by his client at a TEDx conference. At the Summit, Craig will be sharing practical ways to talk about your work in a way that engages your colleagues and brings about positive change.
Show LessJuan Lopez-Mattei
Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR is the co-director and co-founder of Cardiac...
Read MoreJuan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR is the co-director and co-founder of Cardiac Radiology Services at University of Texas MD Anderson Cancer Center, a comprehensive cardiac imaging center of excellence consisting of a Cardiac CT/MRI service dedicated to cancer patients and survivors. He is an associate professor of Medicine and Radiology at University of Texas MD Anderson Cancer Center. Dr. Lopez-Mattei is a nationally recognized expert, with over 80 peer-reviewed publications in the fields of cardio-oncology, echocardiography, cardiovascular computed tomography and cardiovascular magnetic resonance. He holds multiple leadership positions in cardiovascular imaging societies such as American Society of Echocardiography, Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. In addition, Dr. Lopez-Mattei was elected to the American College of Cardiology Emerging Faculty Leadership Academy in 2019 , to the American Society of Echocardiography’s Leadership Academy in 2020 and in 2021 he was elected as member of American College of Cardiology CV Imaging Section Leadership Council. He is also a member of the Certification Board of Cardiovascular Magnetic Resonance (CBCMR) Assessment Committee and a member of the editorial boards of Journal of Cardiovascular Magnetic Resonance and JACC: Cardio-Oncology. He trained as a general cardiologist in Puerto Rico and pursued further training in cardiovascular imaging at Houston Methodist Hospital and is currently qualified as level 3 in echocardiography, cardiac CT and Cardiac MRI.
Show LessMaryam Lustberg
Dr Maryam Lustberg is an Associate Professor with Tenure in the Division of Medical Oncology at...
Read MoreDr Maryam Lustberg is an Associate Professor with Tenure in the Division of Medical Oncology at The Ohio State University, where she specialize in treating patients with breast cancer at The Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). In July 1, she joins Yale School of Medicine as an Associate Professor, Chief of Breast Medical Oncology and the Director of Yale Breast Center. Her research focuses on improving long-term outcomes for breast cancer patients who have developed side effects associated with treatment, and on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She joined the Division of Medical Oncology in August 2010 after completing internal medicine residency at the University of Maryland and a three-year combined medical oncology and breast medical oncology fellowship at Ohio State (2007-2010). She also obtained a Master’s of Public Health (MPH) in Clinical Investigation from Ohio State’s College of Public Health in 2010. She is physician champion and translational researcher in cancer supportive care services focusing on expanding research, clinical care and programs for individuals diagnosed with cancer and serves on the MASCC Board of Directors. She is serving as President Elect of MASCC from 2020 – 2022.
Show LessRandall Oyer
Randall A. Oyer, MD is a practicing medical oncologist at the Ann B. Barshinger Cancer Institute...
Read MoreRandall A. Oyer, MD is a practicing medical oncologist at the Ann B. Barshinger Cancer Institute at Penn Medicine Lancaster General in Lancaster, Pennsylvania. Dr. Oyer serves as the Medical Director of the Cancer Institute, Medical Director of Oncology, Chairman of Cancer Committee, Chair of the Oncology Physicians Advisory Council, and Medical Director of the Cancer Risk Evaluation Program at Penn Medicine Lancaster General. Dr. Oyer is a member of the Cancer Service Line Executive Committee and the Cancer Service Line Quality Committee at the Abramson Cancer Center – University of Pennsylvania, Philadelphia. Dr. Oyer is also a member of the Board of Directors, and President-Elect of the Association of Community Cancer Centers, Rockville, Maryland. Dr. Oyer is an ex-officio Commissioner of the American College of Surgeons Commission on Cancer, representing the Association of Community Cancer Centers. He also is a member of the National Cancer Policy Forum at the National Academies of Science, Engineering, and Medicine.
Show LessTeresa Lopez-Fernandez
Teresa López-Fernández is a clinical investigator and consultant cardiologist at La Paz...
Read MoreTeresa López-Fernández is a clinical investigator and consultant cardiologist at La Paz University Hospital in Madrid, Spain. She is specializes in cardiac imaging (she is board certified in advanced and transesophageal echocardiography by the European Society of Cardiology (ESC)) and cardio-oncology (she is board certified by the International Cardio-Oncology Society), and currently coordinates the cardio-oncology team at La Paz University Hospital. She is the founder and chair of the Spanish Cardio-Oncology Working Group at the Spanish Society of Cardiology (SEC) and the Secretary of the ESC Council of Cardio-Oncology.
Show LessVijay Rao
Dr. Vijay Rao is the Director of CardioOncology, Heart Failure, and Anticoagulation at Franciscan...
Read MoreDr. Vijay Rao is the Director of CardioOncology, Heart Failure, and Anticoagulation at Franciscan Health, Indianapolis, Indiana. He graduated with a dual degree MD and PhD from the Medical University of South Carolina followed by Internal Medicine training at Duke University Medical Center. He then completed Cardiology fellowship at the University of California, San Francisco followed by a dedicated additional year in echocardiography serving as the Chief Fellow. He is the governor-elect for the Indiana Chapter of the American College of Cardiology. Under his leadership, the Franciscan CardioOncology team was awarded an Associate of Community Cancer Centers National Innovator Award in 2020 for “Nurse Navigation as a Model for Developing an CardioOncology Program.” Dr. Rao was also the first author on a recent State of the Art Review published in Journal of American College of Cardiology June 2021 issue titled “Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents.” He also serves as the Chair of the ICOS Center of Excellence Committee and is an active member of the ICOS Education Committee.
Show LessSession 5 - Keynote Debate: Imaging Guided Cardioprotective Strategies – Ready for Prime Time?
From this debate you will learn more about:
• The SUCCOR study trial design and primary outcomes
• Strengths and limitations of the study
• Interpretation of the results from both two opposing perspectives
Chairs:
Jennifer Liu and Dinesh Thavendiranathan
Debators:
Tom Marwick – Yes, Image guided cardioprotective strategies are ready for prime time
Ron Witteles – No, Image guided cardioprotective strategies are NOT ready for prime time
Dinesh Thavendiranathan
Dr. Dinesh Thavendiranathan is a cardiologist at the Peter Munk Cardiac Center at the Toronto...
Read MoreDr. Dinesh Thavendiranathan is a cardiologist at the Peter Munk Cardiac Center at the Toronto General Hospital, University of Toronto. He is an Associate Professor of medicine and a Clinician Scientist. Dr. Thavendiranathan’s Clinical work involves cardiac MRI, CT, and echocardiography and Cardio-oncology. He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity. He holds a Canada Research Chair in Cardio-oncology.
Show LessJennifer Liu
Dr Liu is a cardio-oncologist with expertise in echocardiography. Her areas of interest include...
Read MoreDr Liu is a cardio-oncologist with expertise in echocardiography. Her areas of interest include developing imaging-based strategies to optimize cardiovascular health in patients with cancer.She is also focused on advancing education and training in the field of cardio-oncology.
Show LessRonald Witteles
Ronald Witteles, MD is Professor of Medicine (Cardiovascular Medicine) at the Stanford University...
Read MoreRonald Witteles, MD is Professor of Medicine (Cardiovascular Medicine) at the Stanford University School of Medicine. In addition to leading the CardioOncology program at Stanford, Dr. Witteles serves as Co-Director of both the Stanford Amyloid Center and the Stanford Multidisicplinary Sarcoidosis Program, and is an Associate Editor for JACC: CardioOncology. He has served as Program Director for the Internal Medicine Residency Training Program at Stanford for over a decade, and in this role directly supverises the training of >140 residents each year.
Show LessThomas H Marwick
Tom Marwick is the Director of Baker Heart and Diabetes Institute. His education was completed...
Read MoreTom Marwick is the Director of Baker Heart and Diabetes Institute. His education was completed at the University of Melbourne, University of Louvain, Belgium and Harvard. His main contributions are in clinical research and research training, and has supervised over 30 research higher-degree students. He was one of the initiators of stress echocardiography, and has made contributions to the prognostic evidence underlying cardiovascular imaging. His main research interests relate to detection of early cardiovascular disease and cost-effective application of cardiac imaging techniques for treatment. He has published over 900 papers, reviews, chapters and editorials, and is an Associate Editor at JACC and Deputy Editor at JACC-Cardiovascular Imaging.
Show LessValue of retrospective analyses: ranking cardiotoxicity of oncological drugs in Prostate Cancer (Non-CME session)
Kathleen Zhang
Dr. Zhang completed medical school and Internal Medicine residency at the University of...
Read MoreDr. Zhang completed medical school and Internal Medicine residency at the University of Pennsylvania, followed by fellowships in Cardiology and Cardio-Oncology at Washington University in St. Louis. She specializes in the cardiovascular care of patients with cancer as well as cardiac amyloidosis at Washington University in St. Louis. She has published over 20 peer-reviewed manuscripts in these areas, and served as an editor for the first edition of The Washington Manual of Cardio-Oncology. She is passionate about improving the diagnosis and treatment of patients with cardiac amyloidosis.
Show LessPatrick Davey
Patrick is a Consultant Cardiologist at Northampton General Hospital. As well as taking calls...
Read MorePatrick is a Consultant Cardiologist at Northampton General Hospital. As well as taking calls from Northants GPs, he also advises GPs around the country as part of our National Consultant Network. Patrick is Honorary Senior Lecturer at the John Radcliffe Oxford and has also held a wide variety of advisory and consultancy posts, including Training Program Director for General Medicine in the Southern East Midlands deanery. He is a board member of the British Cardiovascular Society and passionate about improving outcomes for patients.
Show LessAnne Blaes
Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the...
Read MoreDr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.
Show LessJoseph Carver
Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the...
Read MoreJoseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.
Show LessMike Fradley
Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology...
Read MoreDr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.
Show LessSusan Dent
Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed...
Read MoreDr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.
Show LessAnne Blaes
Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the...
Read MoreDr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.
Show LessJoseph Carver
Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the...
Read MoreJoseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.
Show LessMike Fradley
Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology...
Read MoreDr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.
Show LessSusan Dent
Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed...
Read MoreDr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.
Show LessMarta Blanco
Ms. Blanco was born in New Orleans, LA to Colombian parents and is fully bilingual and...
Read MoreMs. Blanco was born in New Orleans, LA to Colombian parents and is fully bilingual and bicultural. She received her undergraduate degree at Louisiana State University (LSU) and is a graduate of Thunderbird – the American Graduate School of International Management. She began her career in Research and has accumulated a wealth of knowledge regarding the importance of consumer insights and their implications for marketing and advertising. Ms. Blanco considers herself more an Account Planner than simply an Account Manager or Research Manager. Currently she works as a consultant on a freelance basis. Ms. Blanco is President of Sofia's Hope, which she founded in honor of her eldest daughter, Sofia. She is dedicated to the foundation and making a difference in the world of pediatric cancer. However, Ms. Blanco has always considered her most important role to be that of the mother to both her girls. She lives in South Florida with her husband, Carlos, and daughter, Gabriela.
Show LessIn this session you will learn more about:
• The role of nurses, pharmacists, and exercise physiologists in the care of cardio-oncology patents
• Strategies to incorporate these professions into your own cardio-oncology practice
• Challenges in developing cardio-oncology practice models for these groups.
Chairs:
Christine Brezden-Masley and Tochukwu Okwuosa
Speakers:
Scott Adams (exercise physiology), Anecita Fadol (nursing), Suzanne McGettigan (nursing), Heather Moore (pharmacy)
Anecita Fadol
Anecita Fadol, PhD, FNP-BC, FAANP, FAAN is an Associate Professor and Education Director, Nursing...
Read MoreAnecita Fadol, PhD, FNP-BC, FAANP, FAAN is an Associate Professor and Education Director, Nursing Cardio-Oncology Program at The University of Texas MD Anderson Cancer Center. Dr. Fadol is a nursing pioneer in the evolving field of cardio-oncology. Her extensive and unique expertise in cardio-oncology have been recognized nationally and internationally. She has written numerous book chapters, published in peer-reviewed journals, and is the editor of the “Cardiac Complications of Cancer Therapy”, the first clinical reference book for nurses that examines the complexity of cardiac problems in conjunction with a cancer diagnosis. Her program of research included the validation of the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF) instrument, which was subsequently translated to Chinese and Spanish. She is on the leadership council for the Cardio-Oncology section of the American College of Cardiology. Dr. Fadol is a fellow of the American Academy of Nurse Practitioners, American Academy of Nursing, and was recently awarded as Honorary Fellow of 2021 by the Hong Kong Academy of Nursing.
Show LessChristine Brezden-Masley
Christine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the...
Read MoreChristine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health in Toronto, Canada. She obtained her PhD in Medical Biophysics at the Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and senior scientist for the same Clinical Research Group at the Lunenfeld-Tanenbaum Research Institute for Sinai Health System in Toronto, Canada. Dr Brezden-Masley is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto region. She treats both breast and gastrointestinal (colorectal and gastric cancers) malignancies, which are her major areas of research interest. Her main area of clinical research is cardiotoxicity from cancer therapy and is currently the President of the Canadian Cardio-Oncology Network. She is also on the Board of Directors of ReThink Breast Cancer, a national advocacy and support network for young women with breast cancer and My Gut Feeling, a stomach cancer support network for patients, survivors, and caregivers.
Show LessHeather Moore
Dr. Moore is originally from eastern North Carolina. She completed her undergraduate degree in...
Read MoreDr. Moore is originally from eastern North Carolina. She completed her undergraduate degree in biology at North Carolina State University and received her doctorate of pharmacy at the UNC Eshelman School of Pharmacy in Chapel Hill. She completed her general residency training at the Durham Veterans Affairs Hospital where she realized her passion for oncology and then continued on to complete oncology residency training at VCU hospital in Richmond, Virginia. After residency, she decided to return home to North Carolina and accepted a position in the breast oncology clinic at the Duke Cancer Institute. She has developed a specific interest in cardio oncology given the cardiotoxicity seen with many breast cancer therapies which led to involvement within the cardio oncology program at Duke. In her free time, she enjoys reading, playing tennis, supporting NC State athletics and spending time with her dog, Chauncey.
Show LessScott Adams
Dr Scott Adams is an Assistant Scientist (Toronto General Hospital Research Institute, University...
Read MoreDr Scott Adams is an Assistant Scientist (Toronto General Hospital Research Institute, University Health Network [UHN]) and the Exercise Lead (Ted Rogers Cardiotoxicity Prevention Program, UHN). He is the Director of the ‘Research in Exercise & Cardiorespiratory Health in Oncology’ laboratory (UHN) and a member of the Adolescent and Young Adult Oncology Program (Princess Margaret Cancer Centre) and the Cardiovascular Prevention and Rehabilitation Program (Toronto Rehab Institute). He completed his PhD at the University of Alberta and two post-doctoral fellowships at Memorial Sloan Kettering Cancer Center and the University of Toronto. His research adopts precision medicine and knowledge translation approaches to (1) phenotype cancer patients and survivors using complementary cardiovascular profiling tools (e.g. cardiopulmonary exercise testing, vascular imaging, autonomic function assessments) to augment cardiovascular risk screening and stratification, (2) develop targeted exercise-based multi-modal therapies that target the discrete mechanisms of risk and injury within these phenotype-defined groups, and (3) facilitate the translation of this and related research into practice.
Show LessSuzanne McGettigan
Suzanne McGettigan, MSN, CRNP, ANP-BC, AOCN is an Oncology Nurse Practitioner and Clinical...
Read MoreSuzanne McGettigan, MSN, CRNP, ANP-BC, AOCN is an Oncology Nurse Practitioner and Clinical Manager of Advanced Practice Providers and Nursing, at the Abramson Cancer Center at the University of Pennsylvania, in the Division of Hematology-Oncology. She has been a part of the Melanoma and Cutaneous Malignancies Program since 2005 as well as other disease based specialties within the Division. She also is a Clinical Associate at the University of Pennsylvania, School of Nursing, in the graduate Nurse Practitioner program. Through her clinical work, Ms. McGettigan has provided care to patients receiving immunotherapy, targeted therapy, and chemotherapy as well as symptom management and survivorship care to cancer patients. She has been a sub-investigator on a number of therapeutic clinical trials. She has published articles in peer reviewed journals detailing nursing and APP care of patients and provided lectures nationally on these topics. After graduating from Washington and Lee University with a Bachelor of Science in Biology, Ms. McGettigan earned both her Bachelor of Science and Master of Science in Nursing from the University of Pennsylvania. Ms. McGettigan holds certification as an Advanced Oncology Nurse and an Adult Nurse Practitioner. She is an active member of the Oncology Nursing Society, the Advanced Practitioner Society for Hematology Oncology, and the Society of Immunotherapy for Cancer.
Show LessTochukwu Okwuosa
Dr. Tochukwu Okwuosa is a cardiologist, Associate Professor of Internal Medicine and the Director...
Read MoreDr. Tochukwu Okwuosa is a cardiologist, Associate Professor of Internal Medicine and the Director of Cardio-Oncology Services at Rush University Medical Center (RUMC). Dr. Okwuosa’s research focuses on identification and prevention of cancer therapy-induced cardiotoxicity. She has received the Cohn’s research award to study markers of cardiotoxicity in breast cancer patients post chemotherapy and the Piccolo-Gavers Translational Research Grant Award for evaluating markers of doxorubicin-induced cardiotoxicity. Okwuosa has also published many peer-reviewed research articles, review articles and editorials in the field of cardio-oncology, including in the Journal of the American College of Cardiology and JAMA. Dr. Okwuosa has spearheaded a number of successful cardio-oncology initiatives at Rush and regionally including the biennial Midwest regional Cardio-Oncology symposium geared toward educating general practitioners involved in the cardiac care of cancer; the triannual Chicago City-wide Cardio-oncology Rounds (CCCR) involving all the major eight Chicago academic institutions; and the biannual Cardio-Oncology patient education seminar series aimed at increasing awareness of and proactiveness in cardiovascular diseases in cancer survivors. She was invited to sit on the Metro Chicago Board for the American Heart Association and is the recipient of numerous awards including Teacher of Year Award for Internal Medicine Residents 2020. She sits on national cardio-oncology committees and writing groups with the American College of Cardiology and the American Heart Association (AHA); is the Vice Chair of the Cardio-Oncology subcommittee for the AHA; and is regionally, nationally and internationally recognized as an expert in cardio-oncology.
Show LessParticipants will choose one topic from session A and one topic from Session B. These sessions are meant to be more intimate and conversational. Once in these virtual conference rooms, participants will be able to turn on their cameras an interact directly with the speakers who will answer questions and provide expert recommendations for managing complex and challenging cases.
Session A
• How Do I Manage Atrial Fibrillation in Patients with Cancer?
Michael Fradley and Stephen Schuster
• How Do I Integrate Cardiac Rehabilitation and Exercise into Survivorship Care?
Susan Gilchrist and Jennifer Ligibel
• How Do I Diagnose and Manage HER2-Related Cardiomyopathy?
Ana Barac and Chau Dang
• How Do I Approach Cardiotoxicity in the Pediatric Patient?
Kasey Leger and Veronica Santos
Session B
• How Do I Manage Acute Coronary Syndromes and Other Vascular Toxicities?
Vivek Narayan and Sebastian Szmit
• How Do I Approach the Management of Cardiovascular Health of Cancer Survivors?
Linda Jacobs and Kevin Oeffinger
• How Do I Diagnose and Treat Checkpoint Inhibitor Associated Myocarditis?
Tomas Neilan and Kerry Reynolds
• How Do I Diagnose and Manage Cardiac Amyloidosis?
Hansie Mathelier and Ashutosh Wechalaker
Ana Barac
Ana Barac, MD PhD is an Associate Professor of Medicine and Oncology at Georgetown University and...
Read MoreAna Barac, MD PhD is an Associate Professor of Medicine and Oncology at Georgetown University and the director of the MedStar Heart and Vascular Institute's Cardio-Oncology program. She specializes in advanced cardiovascular imaging and cardiovascular care of oncology patients. Dr Barac serves an Associate Editor of JACC Cardio-Oncology and a co-director of the ACC Live Course on Advancing CV Care of Oncology patient. She was the founding Chair of the American College of Cardiology (ACC) Cardio-Oncology Council.
Show LessAshutosh Wechalekar
Ashutosh Wechalekar is Professor of Medicine and Haematology at University College London and...
Read MoreAshutosh Wechalekar is Professor of Medicine and Haematology at University College London and Honorary Consultant Haematologist at University College London Hospital/Royal Free Hospital, London, UK. His clinical and research is focused on amyloidosis with a particular interest in cardiac amyloidosis. He leads the AL program for UK. His is the director of the Jack O’Neil Amyloidosis laboratory which is focused on amyloid typing and genomics. He leads UK’s first dedicated amyloidosis treatment clinic at University College London Hospitals and is leading development of a UK National Amyloidosis Treatment Network. He leads AL amyloidosis treatment and research in the UK. His research interests including the development of better risk stratification of the disease, reducing early cardiac mortality in AL, imaging, clonal biology and new treatment strategies in AL amyloidosis. He leads on several national and international clinical trials in AL amyloidosis and myeloma at UCL and has published extensively in the respective areas.
Show LessChau Dang
Dr Dang is a board-certified medical oncologist and works as part of a multidisciplinary team to...
Read MoreDr Dang is a board-certified medical oncologist and works as part of a multidisciplinary team to care for patients with breast cancer. In her clinical research, she focuses on developing more-effective and less-toxic treatment strategies for women with this disease. Her particular interest is in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer.
Show LessHansie Mathelier
Dr. Hansie Mathelier is Clinical Assistant Professor of Medicine at the University of...
Read MoreDr. Hansie Mathelier is Clinical Assistant Professor of Medicine at the University of Pennsylvania. She completed fellowships in Cardiology and Advanced Heart Failure and Transplantation at the University of Pennsylvania. Her clinical areas of expertise include heart failure management, cardio-oncology, cardiac amyloidosis, and mechanical circulatory support. Her clinical interest in cardiology, particularly heart failure, was derived from her time at MIT where she studied chemical engineering. During her medical school and residency training at Johns Hopkins, she was able to integrate engineering and medicine. Her curiosity in cardio-oncologist - started with her interest in cardiac amyloidosis. She has had the privilege to be part of a Center of Excellence for Amyloidosis involving a multidisclipinary approach to the diagnosis and management of this complex disease. She has served as a sub-PI on multiple clinical trials focusing on both amyloidosis and ventricular assist device. She currently serves on the Heart Failure Disease Quality and Cardio-Oncology team for the University of Pennsylvania Health System given her interest in effective treatment of heart failure patients. Her clinical interest is the intersection between cardio-oncology and advanced heart failure.
Show LessJennifer Ligibel
Dr. Jennifer Ligibel is an Associate Professor at Harvard Medical School and the Director of the...
Read MoreDr. Jennifer Ligibel is an Associate Professor at Harvard Medical School and the Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living, as well as the Director of the Center for Faculty Well-Being at the Dana-Farber Cancer Institute. Dr. Ligibel’s research focuses on the impact of energy balance factors, such as physical activity and body weight, upon cancer risk and outcomes. She has evaluated the impact of exercise and weight loss interventions on endpoints such as biomarkers associated with cancer risk and outcomes, fitness, body composition, and quality of life in cancer patients and survivors. Dr. Ligibel is currently leading the Breast Cancer Weight Loss (BWEL) Trial, an NCI-funded Phase III clinical trial that is testing the impact of a weight loss intervention upon the risk of disease recurrence in more than 3100 overweight and obese women with early-stage breast cancer. Dr. Ligibel is also a scientific advisory board member and principal faculty for an R-25 funded workshop focused on training junior investigators interested in cancer energetics. Through this role and other research projects, Dr. Ligibel has had the privilege of working with many early-career faculty interested in the role of lifestyle factors in cancer prevention and control. Finally, Dr. Ligibel is a Fellow of the American Society of Clinical Oncology, the immediate past-chair of the ASCO Cancer Prevention Committee, and the Chair of the ASCO Subcommittee on Energy Balance, which strives to raise awareness in the oncology community of the role that obesity and related factors play in influencing cancer risk and outcomes.
Show LessKasey Leger
Dr. Kasey Leger is a pediatric oncologist at Seattle Children’s Hospital with expertise in the...
Read MoreDr. Kasey Leger is a pediatric oncologist at Seattle Children’s Hospital with expertise in the areas of hematologic malignancies and cancer therapy associated cardiotoxicity. Dr. Leger is a Scholar in Clinical Research of the Leukemia & Lymphoma Society. She leads the Children’s Oncology Group (COG) Myeloid Cardiotoxicity Working Group and the cardiac correlative studies embedded in the ongoing COG phase III randomized trial of CPX-351 in children with de novo acute myeloid leukemia (AML). This study aims to evaluate strategies of primary cardioprotection and inform the utility of sensitive echocardiographic measures of myocardial function and cardiac biomarkers in predicting global cardiac dysfunction. Additionally, Dr. Leger is the principal investigator of the Seattle Children’s Cardiotoxicity Cohort Study assessing novel blood and imaging based markers of cardiotoxicity. Dr. Leger’s overarching research goals are to reduce the toxicity of cancer therapy through primary cardioprotective interventions and identify validated risk predictors to guide secondary/ tertiary cardioprotection and ultimately contribute to long-term leukemia cure without the burden of life-threatening heart disease during survivorship.
Show LessKerry Reynolds
Dr. Kerry Reynolds is an oncologist at the Massachusetts General Hospital Cancer Center and...
Read MoreDr. Kerry Reynolds is an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications (SIC) Service and the Clinical Director for Inpatient Cancer Services at Mass General Cancer Center. She joined the Harvard Medical School faculty in 2014, after completing her residency and chief residency at Massachusetts General and fellowship training in Oncology at Dana-Farber/Partners Cancer Care. The SIC Service is the first program of its kind in the country. Every hospitalized patient at Mass General Cancer Center who has received immunotherapy and is suspected to be experiencing an immune-related adverse event (irAE) is seen by one of the Service’s dedicated oncologists, resulting in unparalleled care for this type of toxicity. Under the leadership of Dr. Reynolds, the SIC Service now provides care to a significant number of patients every year and has grown to comprise more than 50 clinicians and researchers across 19 different areas of the hospital, including subspecialists from oncology, cardiology, dermatology, gastroenterology, and many more relevant disciplines. In addition to providing clinical care, supervising and educating trainees, and participating in administrative affairs, Dr. Reynolds leverages the work of the SIC Service to conduct research on the severe toxicities associated with immunotherapy. Her ultimate goal is to improve the lives of patients undergoing immunotherapy by uncovering irAE predictors and biomarkers, characterizing the clinical presentations of irAEs, developing best practices for managing irAEs, and elucidating the mechanisms that drive irAEs in order to develop novel therapies. To pursue this goal, she is working with Dr. Alexandra-Chloe Villani to systematically collect blood and tissue samples from patients with irAEs and analyze them using cutting-edge technologies. Dr. Reynolds has also authored numerous peer-reviewed publications and several book chapters, and she was lead editor of Facing Immunotherapy: A Guide for Patients and Their Families.
Show LessKevin Oeffinger
Kevin Oeffinger, MD, is a family physician, Professor in the Department of Medicine, and a member...
Read MoreKevin Oeffinger, MD, is a family physician, Professor in the Department of Medicine, and a member of the Duke Cancer Institute (DCI). He is founding Director of the DCI Center for Onco-Primary Care, and Director of the DCI Supportive Care and Survivorship Center. He has a long-standing track record of NIH-supported research in cancer screening and survivorship and has served in a leadership capacity in various cancer-focused and primary care-focused national committees and organizations, including the American Society of Clinical Oncology, the American Cancer Society, and the American Academy of Family Physicians. He is currently an Associate Editor for the Journal of the National Cancer Institute. The three-fold mission of the DCI Center for Onco-Primary Care are are to: (1) deliver evidence-based, patient-centered, personalized health care across the cancer continuum by enhancing the interface between cancer specialists and primary care clinicians; (2) conduct innovative research with cutting-edge technology that can be translated to the community setting; and (3) train and educate the next generation of clinicians and researchers to extend this mission. Dr. Oeffinger's clinical expertise is managing survivors of pediatric and young adult cancer.
Show LessLinda Jacobs
Dr. Jacobs is the founding Director of the Cancer Survivorship Program at Penn Medicine’s...
Read MoreDr. Jacobs is the founding Director of the Cancer Survivorship Program at Penn Medicine’s Abramson Cancer Center, the first adult cancer survivorship program in the US, established in 2001. She is a clinician and researcher, providing follow-up care to numerous populations of cancer survivors including testicular and survivors of childhood and young adult cancers. The Penn Cancer Survivorship Program is a national and internationally renowned clinical, research, and education focused multidisciplinary initiative, and Dr. Jacobs has led the effort to develop models of care, research initiatives, and to identify the education needed to prepare providers to care for cancer survivors. Her multidisciplinary research agenda primarily examines the long-term and late effects of cancer treatment experienced by survivors resulting from their diagnosis with particular emphasis on cardiovascular, endocrine, quality of life, and health behavior modification.
Show LessMaria Veronica Camara dos Santos
Pediatric Cardiologist and Echocardiographer Member, IC-OS Pediatric Cardio-Oncology...
Read MorePediatric Cardiologist and Echocardiographer Member, IC-OS Pediatric Cardio-Oncology Committee Coordinator, Pediatric Cardio-Oncology Committee, Brazilian Society of Pediatric Oncology Coordinator, Pediatric Cardio-Oncology Committee, Brazilian Society of Cardiology
Show LessMike Fradley
Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology...
Read MoreDr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.
Show LessSebastian Szmit
Sebastian Szmit graduated from the Military Medical Academy in Poland. He began cardio-oncology...
Read MoreSebastian Szmit graduated from the Military Medical Academy in Poland. He began cardio-oncology activities in 2006 working for the Department of Oncology of the Military Institute of Medicine. He was appointed the executive editor of the Task Force of National Consultants in Cardiology and Clinical Oncology, and developed the first two Polish Recommendations on cardiovascular safety of patients with breast cancer (published in 2010) and lung cancer (published in 2012). Since 2012 he has served as the cardio-oncology consultant at the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, at the Centre of Postgraduate Medical Education in Poland. In 2015 he was appointed as the scientific director of the "Oncology in Cardiology" training program. He is the cardio-oncology research coordinator for the Polish Lymphoma Research Group and the Polish National Oncology Network. He co-authored two educational books: "Hypertension-oncology: arterial hypertension in cancer disease" and "Cardiovascular complications in cancer patients" published in 2018 under auspices of the Polish Society of Clinical Oncology, Since 2019 he has been a Member of the Executive Committee of the Global Cardio-Oncology Summit (GCOS) and a Member of the Education & Training Advisory Committee of the International Cardio-Oncology Society (ICOS) and in 2020 he was awarded an Honorary Member of the Cardio-Oncology Society of Southern Africa (COSOSA), a Fellow of the International Cardio-Oncology Society (FICOS), and a Board Member of the European Society of Cardiology (ESC) Council of Cardio-Oncology. On May 26th 2021, Dr. Szmit was asked by the Scientific Council of the Centre of Postgraduate Medical Education to lead the newly created "Cardiooncology Department and Echocardiography Laboratory" based at the European Health Centre in Otwock (oncology center) and the Institute of Hematology and Transfusion Medicine in Warsaw.
Show LessStephen Schuster
Stephen J. Schuster, MD is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma...
Read MoreStephen J. Schuster, MD is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the Director of the Lymphoma Program and Director of Lymphoma Translational Research at the Abramson Cancer Center. After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College. Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous costimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, bispecific antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells) He has over 300 publications and has received numerous awards for outstanding teaching and research.
Show LessSusan Gilchrist
Dr. Gilchrist is an expert in cardiovascular prevention with a special focus on patients with...
Read MoreDr. Gilchrist is an expert in cardiovascular prevention with a special focus on patients with cancer. She has a VO2 testing lab within her clinical practice, providing objective cardiorespiratory fitness assessment and personalized exercise prescriptions for patients. This is the first cardiovascular prevention program in the U.S. focused exclusively on improving fitness and mitigating existing cardiovascular risk factors in patients treated for cancer. Dr. Gilchrist’s clinical research program focuses on epidemiological studies relating fitness to cancer outcomes and clinical studies to assess the optimal intensity, duration, and timing of exercise training in the chemoprevention setting as well as during and after cancer treatment.
Show LessTomas Neilan
Dr. Neilan received his M.D. from University College Dublin and MPH from Harvard School of Public...
Read MoreDr. Neilan received his M.D. from University College Dublin and MPH from Harvard School of Public Health. He completed internal medicine residency and cardiology training at the Mater Misericordiae Hospital in Dublin and again at Massachusetts General Hospital. He has also completed extensive training in echocardiography at Massachusetts General Hospital and cardiac magnetic resonance at the Brigham and Women's Hospital. Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program and the Co-Director of the Cardiac MR PET CT Program. Dr. Neilan has had a long-standing clinical and research interest in the cardiovascular care of patients with cancer. Cardiovascular disease is a leading cause of death and disability among cancer survivors and cardiovascular care for patients with cancer requires a tailored approach that is unique for each patient. He is specifically interested in how we can improve on the methods for detection of the cardiac toxicity after chemotherapy and radiotherapy and to use that information to determine how we care for patients.
Show LessVivek Narayan
Dr. Vivek Narayan, MD MSCE is an Assistant Professor of Medicine in the Division of Medical...
Read MoreDr. Vivek Narayan, MD MSCE is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Pennsylvania Abramson Cancer Center. His clinical and research interests are specifically focused on the care of patients with advanced prostate cancer and kidney cancer. He serves as principal investigator on several therapeutic oncology clinical trials, including multiple investigator-initiated studies. He additionally seeks to improve survivorship care for patients with cancer, including the evaluation and management of cardiac toxicities of cancer therapies for prostate and kidney cancers. Dr Narayan’s early career achievements have been nationally recognized, with selection as the 2018 AUA Urology Care Foundation Outstanding Graduate Scholar Award, as well as a recipient of the 2018 Prostate Cancer Foundation Young Investigator Award. He has received research funding from the American Cancer Society, American Urological Association, and the Prostate Cancer Foundation.
Show LessChair: Dan Lenihan
Speaker: Bonnie Ky
Bonnie Ky
I am a tenured Associate Professor of Medicine and Epidemiology and physician scientist at the...
Read MoreI am a tenured Associate Professor of Medicine and Epidemiology and physician scientist at the University of Pennsylvania. My fundamental goals are to gain insight into the underlying mechanisms and predictors of cancer therapy cardiotoxicity, and to translate this understanding to the clinical care of patients. I lead a highly active NIH-funded translational research program in cardio-oncology and am the PI of multiple investigator-initiated cohort studies and clinical trials focused on the study of the cardiotoxic effects of doxorubicin, trastuzumab, anti-angiogenic tyrosine kinase inhibitors, androgen deprivation therapy, and radiation therapy in breast, renal cell, prostate and lung cancers, and lymphoma patients. My programmatic objectives are to understand how we can improve cardiovascular outcomes in cancer patients by determining individual patient risk, through detailed phenotyping of clinical characteristics, the social determinants of health, biologic markers, and echocardiography-derived measures of myocardial mechanics and function. I also serve as the Director for the Penn Center for Quantitative Echocardiography and the Founding Director of the Penn Cardio-Oncology Translational Center of Excellence and have built a strong, multi-disciplinary collaborative network comprised of highly successful basic, translational, and clinical researchers. I am an invited member of many cardio-oncology expert consensus and research groups within the NIH, FDA, American Society of Clinical Oncology, American College of Cardiology, American Heart Association, and European Society of Cardiology focused on advancing our understanding of cardiovascular disease in the growing cancer population. I am the Inaugural Editor-in-Chief of JACC: CardioOncology, and successfully launched this important scientific and clinical resource. I have specialized expertise in cardio-oncology, epidemiology, the study of biomarkers, and imaging tools to understand cardiac remodeling, function, and risk prediction.
Show LessDaniel Lenihan
Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main...
Read MoreDr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Show LessParticipants will choose the breakout session most suited to their needs. Once inside the virtual conference rooms, participants will be able to turn on their cameras an interact directly with the speakers who will discuss their personal career paths and answer any questions.
Fellowship Training Programs in Cardiology
Chair
Joe Carver
Panelists
Husam Abdel-Qadir, Mary Branch, Benedicte Lefebvre, Josh Mitchell, Shruti Patel
Leveraging ICOS for Career Development
Chair
Susan Dent
Panelists
Raul Cordoba Sarju Ganatra, Alex Lyon, Ariane Macedo, Charles Porter
Career Pathways in Cardio-Oncology
Chair
Anne Blaes
Panelists
Daniel Addison, Daniela Cardinale, Charlotte Manisty, Javid Moslehi, Lova Sun
Alexander Lyon
Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant...
Read MoreDr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome and the effects of major stresses of the heart, and the development of novel therapeutics including gene therapy for chronic heart failure. Alex has published over 180 scientific papers in peer-reviewed journals, several book chapters in cardiology textbooks including the chapter on cardiotoxicity of tyrosine kinase inhibitors in the latest edition of the ESC Textbook of Cardiology. He is a deputy editor of the European Heart Journal, an associate editor of the European Journal of Heart Failure, international advisor to the journal JACC Cardio-Oncology and his H-index is 44. Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Alex is the current president of the British Cardio-Oncology Society, recently appointed a board member of International Cardio-Oncology Society (ICOS - 2021), chair-elect European Society of Cardiology (ESC) Council of Cardio-Oncology (2020-2022) and he is the cardiology advisor to the charity Macmillan Cancer. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025 ($6M). Alex is a co-chair of the first ESC Cardio-Oncology Guideline which will be published in 2022. Alex completed a full 4 year term on the board of the Heart Failure Association of the ESC (2016-2020), and he initiated and was the chair of the Heart Failure Association Cardio-Oncology Study Group. He is a co-author of the ESC Position Statement on Cardio-Oncology, the ESC Cardio-Oncology Council article on the setting up and delivery of Cardio-Oncology services and the 2020 ESMO guidelines on the management of cardiac diseases in cancer patients. He is a member of the International Cardio-Oncology Society and Alex was co-chair of the 2017 Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London in September 2017.
Show LessAnne Blaes
Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the...
Read MoreDr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.
Show LessAriane Macedo
Dra. Macedo is an assistant physician and coordinator of the cardio-oncology clinic at Santa Casa...
Read MoreDra. Macedo is an assistant physician and coordinator of the cardio-oncology clinic at Santa Casa de São Paulo School of Medicine, São Paulo, Brazil. She is also chair of the cardio-oncology department of Rede D’Or São Luiz health network and researcher/faculty at BCRI (Brazilian Clinical Research Institute). Her clinical background includes MD and Master in Health Sciences at the University of Minas Gerais, Brazil. Currently, she is finishing the Ph.D. program at the Federal University of São Paulo, Brazil. She is an active member of scientific organizations serving now as Vice President of the cardio-oncology chapter of the Brazilian Society of Cardiology, Director of the Brazilian Society of Thrombosis and Hemostasis, and Member of the Council of Cardio-Oncology of the Interamerican Society of Cardiology. In 2019 she was certified to be a fellow of the European Society of Cardiology. She is currently developing consensus documents in cardio-oncology and the definition of core educational topics to provide structured training in cardio-oncology.
Show LessBenedicte Lefebvre
Dr. Bénédicte Lefebvre is an Assistant Professor of Clinical Medicine at the University of...
Read MoreDr. Bénédicte Lefebvre is an Assistant Professor of Clinical Medicine at the University of Pennsylvania. Dr. Lefebvre earned her medical degree from McGill University, Montreal, Canada where she also completed her training in internal medicine and general adult cardiology. She then completed a two-year fellowship in advanced cardiac imaging at the University of Pennsylvania specializing in echocardiography, structural echocardiography and cardiac magnetic resonance. Afterwards, she underwent a cardio-oncology fellowship at the University of Pennsylvania. Dr. Lefebvre’s research focuses on the cardiovascular effects of CAR T cells and the use of cardiac imaging and biomarkers to detect cardiotoxicity.
Show LessCharles Porter
Charles Porter MD established the Cardio-oncology program for the University of Kansas Cancer at...
Read MoreCharles Porter MD established the Cardio-oncology program for the University of Kansas Cancer at the University of Kansas Medical Center in 2007. He was designated as the inaugural American Vice-President of IC-OS in 2009. He has overseen the growth of the KUMC cardio-oncology program and continues to expand its collaboration with a broad array of oncologists in patient care and research. Research includes studies in BMT outcomes, 5FU cardiotoxicity and breast cancer treatment cardiotoxicity. He is associate editor for Cardiooncology, an editorial consultant for JACC Cardiooncology, and is a member of the IC-OS Science and Research Committee. He has multiple publications and presentations in the field.
Show LessCharlotte Manisty
Charlotte Manisty is Associate Professor of at University College London and set up and leads the...
Read MoreCharlotte Manisty is Associate Professor of at University College London and set up and leads the largest cardio-oncology service in the UK at Barts Hospital, London. She and also has expertise in heart failure and cardiac imaging, and leads a research group whose current research interests include optimising imaging using computational techniques for identifying patients at risk of developing cardiotoxicity, and understanding the vascular toxicity of chemotherapeutic agents. She chairs the SCMR Cardio-oncology group, and is Research Lead for British Cardio-oncology Society. She is regularly invited to speak both Nationally and at International conferences on Cardio-oncology and Imaging, and chairs the UK Multi-Societal Working Group on MRI in patients with cardiac devices. She receives funding for her work from BHF and NHLI, and has published over 100 papers and book chapters, alongside supervising PhD students and teaching.
Show LessDaniel Addison
Dr Addison is a clincal inviestigator and practicing cardiologist with unique expertise in...
Read MoreDr Addison is a clincal inviestigator and practicing cardiologist with unique expertise in cardiovascular imaging and cardio-oncology. He completed his Medicine and General Cardiology training at Baylor College of Medicine in 2015. He joined The Ohio State University following the completion of a NIH T-32 advanced cardiovascular imaging fellowship at Massachusetts General Hospital in Boston, MA, where he focused in cardio-oncology. He currently serves as co-director of the Cardio-Oncology Program at the Ohio State Comprehensive Cancer Center, where he employs advanced imaging techniques to understand the pathophysiologic mechanisms and potential targets of interventions for cardiovascular disease(s) among cancer survivors at risk for cardiovascular events. To date, his efforts focus on the interplay of cancer-treating radiotherapy and cardiovascular events, the early detection of anthracycline-associated cardiotoxicity, and the early detection and mechanisms of cancer targeted and immunotherapy-associated cardiovascular diseases, for which I am supported by the NCI, AHA, and RWJ.”
Show LessDaniela Cardinale
Dr. Daniela Cardinale is specialized in Cardiology. She holds a PhD in Cardiovascular...
Read MoreDr. Daniela Cardinale is specialized in Cardiology. She holds a PhD in Cardiovascular Physiopathology in 2009. She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan. Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment.
Show LessHusam Abdel-Qadir
Husam Abdel-Qadir is a cardiologist at Women’s College Hospital and the Peter Munk Cardiac...
Read MoreHusam Abdel-Qadir is a cardiologist at Women’s College Hospital and the Peter Munk Cardiac Centre, and a scientist at Women’s College Research Institute, the Ted Rogers Centre for Heart Research, and ICES. He graduated from the University of Toronto’s medical school with the Silver Medal and completed residencies in Internal Medicine and Cardiology at the University of Toronto. During his training, Dr. Abdel-Qadir became interested in optimizing the cardiovascular health of people who are less likely to be represented in clinical trials. This motivated him to pursue a PhD in Clinical Epidemiology and Health Care Research at the Institute for Health Policy, Management, and Evaluation. His PhD thesis focused on the cardiovascular health of women with breast cancer, and this continues to be a focus of his research program. His clinical and research expertise also extends to the cardiovascular health of people with other cancers. He is also developing a research program on the management and outcomes of people with atrial fibrillation. His research is supported by an early career Chair in Heart and Brain Health and the 2020 National New Investigator Award from the Heart and Stroke Foundation of Canada. He has also received the Canadian cardiovascular Society Atrial Fibrillation Research Award, European Society of Cardiology Young Investigator Award, the inaugural Young Investigator Competition at the 2017 Global Cardio-Oncology Summit, and the 2018 Polanyi prize in Medicine/ Physiology. Dr. Abdel-Qadir also sits on the board of the Black Physicians’ Association of Ontario and serves as its Director of Continuing Professional Development.
Show LessJavid Moslehi
He is a cardiologist and myocyte biologist. his clinical focus is cardio-oncology (the...
Read MoreHe is a cardiologist and myocyte biologist. his clinical focus is cardio-oncology (the cardiovascular care of cancer patients and cancer survivors). His basic and translational NIH-funded laboratory addresses myocardial responses to various stresses including hypoxia, aging and toxins. Over the last several years, given his clinical interest in cardio-oncology, his laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. He believes because of the targeted nature of the toxicities, cardio-oncology can provide insights into novel signalling pathways that are relevant in human cardiovascular biology and pathology. At Vanderbilt, He is an Associate Professor of Medicine, Director of Cardio-Oncology and Co-director of Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT). He works closely with cardiologists and oncologists, basic, translational researchers and clinicians locally, nationally and internationally. He has also started several collaborations with industry and regulatory bodies (including the US FDA). He was recently named the first chair of the American Heart Association (AHA) cardio-oncology subcommittee. At Vanderbilt, he has established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology. He is an elected member of American Society of Clinical Investigation (ASCI).
Show LessJoseph Carver
Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the...
Read MoreJoseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.
Show LessJoshua Mitchell
Joshua Mitchell, MD, MSCI is an Assistant Professor of Medicine and Director of the...
Read MoreJoshua Mitchell, MD, MSCI is an Assistant Professor of Medicine and Director of the Cardio-Oncology Fellowship at the Cardio-Oncology Center of Excellence, Washington University School of Medicine in St. Louis. Prior to coming to Washington University in 2015, he served 11 years in the US Army, deploying with the 82nd Airborne Division and the 75th Ranger Regiment, earning two Bronze Start Medals, and reaching the rank of Major. He is currently a member of the ICOS Scientific Committee and recently helped lead the 2021 ICOS expert consensus statement for cardiovascular disease screening in radiation survivors. He also serves on the JACC:Cardio-Oncology editorial board and is the Co-Chair for the ACC Cardio-Oncology working group. His clinical and research interests include better characterizing and understanding cardiovascular disease associated with cancer treatment, and the diagnosis of management of cardiac amyloidosis. His research has also focused on the use of coronary artery calcium to improve risk prediction and help target preventive therapy. As the Cardio-Oncology fellowship director at Washington University in St. Louis, he has directed the training and development for full year fellows, rotations for internal cardiology fellows, and rotations for both external cardiology fellows and for board certified cardiologists looking for additional training in Cardio-Oncology to improve their practice.
Show LessLova Sun
Dr. Lova Sun is an Assistant Professor in the Division of Hematology/Oncology at the University...
Read MoreDr. Lova Sun is an Assistant Professor in the Division of Hematology/Oncology at the University of Pennsylvania. Her clinical focus is head/neck and lung cancers, and her research interests include improving survivorship and cardiovascular outcomes in patients with cancer.
Show LessMary Branch
Mary Branch is an administrator at Wake Forest Baptist Medical Center, Winston Salem, USA.
Read MoreMary Branch is an administrator at Wake Forest Baptist Medical Center, Winston Salem, USA.
Show LessRaul Cordoba
Dr Raul Cordoba is Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital,...
Read MoreDr Raul Cordoba is Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. He obtained his Bachelor of Medicine degree from the Autonomous University of Madrid and went on to specialise in haematology at the University Hospital La Princesa, Madrid. He first started his research in the field of lymphoid neoplasms, achieving his Master’s degree in Molecular Oncology from the Spanish National Cancer Research Centre, Madrid, and his PhD from the Department of Medicine at the Autonomous University of Madrid. He is also the Principal Investigator for the Haematology Programme of START Madrid-FJD, a unit dedicated exclusively to Phase I trials in oncology. He serves as the vice-president of the Spanish Group of Geriatric Hematology of the Spanish Society of Hematology and Hemotherapy (SEHH) since 2012. He is the chair of the EHA-Scientific Working Group "Aging and Hematology"" of the European Hematology Association (EHA) since 2019. Since 2014, Dr Cordoba is the National Representative of the International Society of Geriatric Oncology (SIOG) in Spain and member of the Board of Directors since 2020. He is member of the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) where he has given lectures in scientific symposia and educational programs with the topic of geriatric hematology.
Show LessSarju Ganatra
Dr Ganatra serves as a Director of the Cardio-Oncology Program and Co-Director of the Cardiac MRI...
Read MoreDr Ganatra serves as a Director of the Cardio-Oncology Program and Co-Director of the Cardiac MRI Program for Lahey Hospital and Medical Center, Beth Israel Lahey Health in Boston. His primary research interest is outcomes research in cardio-oncology. He serves on the Research and Scientific Committee of the International Cardio-Oncology Society (ICOS), the American College of Cardiology Cardio-Oncology leadership council, and on the editorial board of JACC Cardio-Oncology.
Show LessShruti Patel
I am a third-year internal medicine resident at Mayo Clinic, Rochester and a rising Oncology...
Read MoreI am a third-year internal medicine resident at Mayo Clinic, Rochester and a rising Oncology fellow at Stanford University. I graduated with degrees in Molecular Biology and Human Development with a minor in Humanities from University of California, San Diego and completed medical school at the Keck School of Medicine at the University of Southern California. Cardio-oncology is one of my primary research interests as preserving cardiac health is a critical component of comprehensive oncologic care. More specifically, I am interested in understanding specific patient factors that put certain patients at higher risk for cardiotoxicity and the utilization of biomarkers for the early detection of impaired cardiac health.
Show LessSusan Dent
Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed...
Read MoreDr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.
Show LessYoung Investigator Finalists
Alis Bonsignore -- Predictors of impaired cardiorespiratory fitness early after cancer therapy in women with HER2+ breast cancer
Zsofia Drobni -- Renin-Angiotensin-Aldosterone System Inhibitors and Overall Survival in Cancer Patients Treated with Immune Checkpoint Inhibitors
Serena Peck -- Associations Between Self-Reported Physical Activity During Therapy and Post-Therapy Cardiorespiratory Fitness and Cardiac Function in Breast Cancer Patients
Judges:
Richard Cheng, Arjun Ghosh, Avirup Guha, Rupal O’Quinn, Katie Ruddy
Arjun Ghosh
Dr Arjun K Ghosh MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS is a Consultant Cardiologist at...
Read MoreDr Arjun K Ghosh MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS is a Consultant Cardiologist at Barts Heart Centre (BHC), St. Bartholomew’s Hospital, London and at University College London Hospital (UCLH). He is the first cardiologist in the UK to be appointed specifically in cardio-oncology and helped establish Cardio-Oncology services at both these hospitals which are now amongst the biggest services worldwide. Arjun leads the cardio-oncology service at UCLH. Arjun is also actively involved in developing cardio-oncology curricula and guidelines and changing practice through the British Society of Echocardiography, British Cardio-Oncology Society and International Cardio-Oncology Society and UK Specialist Advisory Committee (SAC). He was joint first author of the first British cardio-oncology guidelines published earlier this year. He runs the UK’s only national Cardio-Oncology Study Day and help organise the only pan-European Cardio-oncology Symposium. Outside of the interesting world of cardiology’s newest subspecialty Arjun is involved in cardiac MRI (CMR) and cardio-oncology echocardiography and has several national and international leadership and management positions at the British Cardiovascular Society, the Royal Society of Medicine, the British Cardio-Oncology Society and the International Cardio-Oncology Society. He is the co-host of the ICOS podcast and has recently been appointed to the ACC Cardio-Oncology Leadership Council. You can find him on Twitter @arjunkg.
Show LessAvirup Guha
Bio: Dr. Guha is an Assistant Professor of Medicine, Case Western Reserve University School of...
Read MoreBio: Dr. Guha is an Assistant Professor of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, and a consultant cardiologist in the Harrington Heart and Vascular Institute. He is an expert in cardiovascular epidemiology pertaining to cardio-oncology. Additionally, he is a faculty member of the Harrington Heart and Vascular Insitute's cardio-oncology program. Finally, he is a member of the JACC: Cardio-oncology and ICOS SoMe working groups.
Show LessKathryn Ruddy
Dr Ruddy is a breast medical oncologist at Mayo Clinic Rochester who co-leads the Symptom...
Read MoreDr Ruddy is a breast medical oncologist at Mayo Clinic Rochester who co-leads the Symptom Control/Survivorship Cross-Disciplinary Group and the Population Sciences Program for Mayo Clinic Cancer Center across all Mayo Clinic sites. Cardiotoxicity is one of her primary research interests, and she is co-PI of an R01-funded clinical trial assessing carvedilol as a cardioprotectant during Her2-directed therapy for breast cancer. she is a member of the NCCN Survivorship Guidelines Committee, a vice chair of the Symptom Intervention Committee in the Alliance for Clinical Trials in Oncology, and an Associate Editor at JNCI and at JACC Cardio-Oncology.
Show LessRichard Cheng
Richard Cheng, MD, MSc is a HF cardiologist and cardio-oncologist with a focus on education, risk...
Read MoreRichard Cheng, MD, MSc is a HF cardiologist and cardio-oncologist with a focus on education, risk stratification, imaging, and treatment strategies for HF, cardiomyopathies, cardiac amyloidosis and cancer therapy-associated cardiac dysfunction. His recent research interests include the prevention of cardiovascular disease, epidemiology, and long-term cardiovascular complications of cancer treatment in breast cancer survivors and stem cell transplant recipients. He also has ongoing studies focused on risk stratification, multimodality imaging and outcomes in cardiac amyloidosis, cardiomyopathies, heart transplantation and LVAD recipients. He serves on the editorial boards of JACC, JACC: Cardio-Oncology, ACC.org, Heart, and the Journal of Heart and Lung Transplantation.
Show LessRupal O’Quinn
Dr. Rupal O'Quinn is an Assistant Professor of Clinical Medicine at the University of...
Read MoreDr. Rupal O'Quinn is an Assistant Professor of Clinical Medicine at the University of Pennsylvania, and the Director of Cardio-Oncology at Penn Presbyterian Medical Center. Dr. O’Quinn joined the faculty in 2015, and specializes in the field of cardio-oncology and multi-modality cardiovascular imaging that includes echocardiography and cardiac magnetic resonance. She is currently on the Research and Scientific Advisory Committee of the International Cardio-Oncology Society (ICOS), as well as a member of the Training in Cardio-Oncology and Cardio-Oncology Advocacy workgroups within the American College of Cardiology. Dr. O'Quinn completed a fellowship at the Hospital of the University of Pennsylvania in 2015, where she focused on Cardio-Oncology. Prior to that, Dr. O'Quinn completed a General Cardiology Fellowship at Beth Israel Deaconess Medical Center - Harvard University Medical School in Boston, Massachusetts with a focus in cardiovascular imaging. She is currently pursuing a Master of Healthcare Innovation at the University of Pennsylvania, with expected completion in May, 2023. Dr. O'Quinn completed her residency and chief medical residency at the University of Michigan Health Systems in Ann Arbor, Michigan. She attended medical school at the Rutgers Medical School/University of Medicine and Dentistry of New Jersey, and college at Boston University where she graduated Summa Cum Laude.
Show LessIn this session you will learn about:
• How to participate in IC-OS
• What are the benefits of joining IC-OS
• Available opportunities including committees and working groups
Chairs:
Anita Arnold and Dan Lenihan
Speakers
Lauren Baldassare Stephen Casselli, Roohi Ismail-Khan, Anju Nohria, Vijay Rao
Anita Arnold
Dr. Arnold is a native New Yorker and studied General and Interventional Cardiology at the...
Read MoreDr. Arnold is a native New Yorker and studied General and Interventional Cardiology at the Cleveland Clinic Foundation in Cleveland, Ohio, USA. As a cancer survivor herself, she is passionate about Cardio-Oncology and presently is an Associate Professor of Medicine at Florida State University, the Founding Director of the Cardio-Oncology program and Transitional Clinic for childhood cancer survivors at Lee Health in Florida, a Board of Director member and Chair of the Education Committee for ICOS, and the past chair of the Advocacy working group for the Cardio-Oncology section of the American College of Cardiology. She is interested in disparities in healthcare especially as it relates to Cardio-Oncology.
Show LessAnju Nohria
Dr. Anju Nohria is the Director of the Cardio-Oncology Program at Dana-Farber/Brigham and Women’s...
Read MoreDr. Anju Nohria is the Director of the Cardio-Oncology Program at Dana-Farber/Brigham and Women’s Cancer Center and a cardiovascular specialist in heart failure and transplantation at Brigham and Women’s Hospital (BWH). In addition, she is an Assistant Professor of Medicine at Harvard Medical School (HMS). Dr. Nohria received her medical degree from HMS. She completed an internal medicine residency and was a chief resident at Yale-New Haven Hospital. She then completed both a cardiovascular medicine fellowship and a heart failure and transplantation fellowship at BWH. She is board certified in cardiovascular disease and heart failure and transplantation. Dr. Nohria’s clinical interests include cardio-oncology and heart failure and transplantation. The author of approximately 100 peer-reviewed publications, she currently researches how to evaluate, prevent and treat cardiovascular complications that can arise as a result of cancer therapy.
Show LessDaniel Lenihan
Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main...
Read MoreDr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Show LessLauren Baldassarre
Lauren A. Baldassarre, MD is Associate Professor of Cardiovascular Medicine and Radiology &...
Read MoreLauren A. Baldassarre, MD is Associate Professor of Cardiovascular Medicine and Radiology & Biomedical Imaging at Yale School of Medicine in New Haven, CT. She is the Director of the Yale Smilow Cancer Center Cardio-Oncology Program and the Cardiology Director of Cardiac MR/CT for Yale New Haven Hospital. She is also the Program Director for the newly established Yale Cardio-Oncology Advanced Fellowship Program. Dr. Baldassarre is a member of the American College of Cardiology Cardio-Oncology Section Leadership Council and is the Chair of the International Cardio-Oncology Society Imaging Work Group. She is the Chair of the Society for Cardiovascular Magnetic Resonance Cardio-Oncology Special Interest Group and is a member of the Society of Cardiovascular Computed Tomography Cardio-Oncology Writing Group. Her clinical and research interests include the use of advanced multimodality cardiac imaging for the detection, management, and prevention of cardiotoxicity from cancer therapeutics.
Show LessRoohi Ismail-Khan
Dr. Roohi Ismail-Khan is a medical oncologist and provides care for cancer patients in the...
Read MoreDr. Roohi Ismail-Khan is a medical oncologist and provides care for cancer patients in the Cardio-Oncology and Survivorship Programs. She has an interest in Women’s Health and has served more than 10 years taking care of Breast Cancer patients and has now joined the gynecologic oncology program at Moffitt Cancer Center. Recently, she has concentrated her clinical efforts to help patients with cancer who also have high risk cardiovascular disease. She works closely with Cardiology in helping patients balance the treatment for their cancer and their co-existing CV disease. She serves as the co-director of the new Cardio-Oncology Program. She completed her Internal Medicine Residency at the University of South Florida and served as chief resident in her final year. She completed her Medical Oncology Fellowship at the H. Lee Moffitt Cancer Center and completed her MS in Clinical Research during her fellowship. Her clinical focus and research is focused upon identifying high risk patient cohorts and minimizing cardiovascular side effects in patients receiving cardio-toxic therapy. Dr. Ismail-Khan is also an active teacher and mentor for USF medical students, Internal Medical residents, and Medical Oncology Fellows.
Show LessStephen Casselli
Dr. Stephen Casselli is an executive director at International Cardio-Oncology Society.
Read MoreDr. Stephen Casselli is an executive director at International Cardio-Oncology Society.
Show LessVijay Rao
Dr. Vijay Rao is the Director of CardioOncology, Heart Failure, and Anticoagulation at Franciscan...
Read MoreDr. Vijay Rao is the Director of CardioOncology, Heart Failure, and Anticoagulation at Franciscan Health, Indianapolis, Indiana. He graduated with a dual degree MD and PhD from the Medical University of South Carolina followed by Internal Medicine training at Duke University Medical Center. He then completed Cardiology fellowship at the University of California, San Francisco followed by a dedicated additional year in echocardiography serving as the Chief Fellow. He is the governor-elect for the Indiana Chapter of the American College of Cardiology. Under his leadership, the Franciscan CardioOncology team was awarded an Associate of Community Cancer Centers National Innovator Award in 2020 for “Nurse Navigation as a Model for Developing an CardioOncology Program.” Dr. Rao was also the first author on a recent State of the Art Review published in Journal of American College of Cardiology June 2021 issue titled “Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents.” He also serves as the Chair of the ICOS Center of Excellence Committee and is an active member of the ICOS Education Committee.
Show LessAnne Blaes
Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the...
Read MoreDr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.
Show LessChristine Brezden-Masley
Christine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the...
Read MoreChristine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health in Toronto, Canada. She obtained her PhD in Medical Biophysics at the Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and senior scientist for the same Clinical Research Group at the Lunenfeld-Tanenbaum Research Institute for Sinai Health System in Toronto, Canada. Dr Brezden-Masley is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto region. She treats both breast and gastrointestinal (colorectal and gastric cancers) malignancies, which are her major areas of research interest. Her main area of clinical research is cardiotoxicity from cancer therapy and is currently the President of the Canadian Cardio-Oncology Network. She is also on the Board of Directors of ReThink Breast Cancer, a national advocacy and support network for young women with breast cancer and My Gut Feeling, a stomach cancer support network for patients, survivors, and caregivers.
Show LessDinesh Thavendiranathan
Dr. Dinesh Thavendiranathan is a cardiologist at the Peter Munk Cardiac Center at the Toronto...
Read MoreDr. Dinesh Thavendiranathan is a cardiologist at the Peter Munk Cardiac Center at the Toronto General Hospital, University of Toronto. He is an Associate Professor of medicine and a Clinician Scientist. Dr. Thavendiranathan’s Clinical work involves cardiac MRI, CT, and echocardiography and Cardio-oncology. He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity. He holds a Canada Research Chair in Cardio-oncology.
Show LessJoseph Carver
Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the...
Read MoreJoseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.
Show LessMike Fradley
Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology...
Read MoreDr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.
Show LessSusan Dent
Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed...
Read MoreDr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.
Show Less